Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Gaelle Muller-Greven"'
Autor:
Wei Michael Liu, Ping Huang, Niladri Kar, Monica Burgett, Gaelle Muller-Greven, Amy S Nowacki, Clark W Distelhorst, Justin D Lathia, Jeremy N Rich, John C Kappes, Candece L Gladson
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e70804 (2013)
Members of the Src family kinases (SFK) can modulate diverse cellular processes, including division, death and survival, but their role in autophagy has been minimally explored. Here, we investigated the roles of Lyn, a SFK, in promoting the survival
Externí odkaz:
https://doaj.org/article/28a1bcb0b36d4560a0b45c51242afaef
Autor:
Lingling Du, Manmeet Ahluwalia, Robert J. Weil, Maha A. Qadan, Amy S. Nowacki, Ruth A. Keri, Nooshin Hashemi-Sadraei, Gaelle Muller-Greven, Thomas Budd, Richard A. Prayson, Candece L. Gladson, Monica E. Burgett, Ilya V. Ulasov, Adam Lauko, Fadi W. Abdul-Karim, Jill S. Barnholtz-Sloan, Erinn Downs-Kelly, Samuel T. Chao
Publikováno v:
Journal of Neuro-Oncology. 140:237-248
Macroautophagy/autophagy is considered to play key roles in tumor cell evasion of therapy and establishment of metastases in breast cancer. High expression of LC3, a residual autophagy marker, in primary breast tumors has been associated with metasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c30b2ff2a5173fc7f5589c1143cf005
https://doi.org/10.1007/s11060-018-2959-5
https://doi.org/10.1007/s11060-018-2959-5
Autor:
Manmeet Ahluwalia, Justin D. Lathia, Maha A. Qadan, Cameron Herting, Amy S. Nowacki, Steven A. Toms, Dolores Hambardzumyan, Gaelle Muller-Greven, Adam Lauko, Petra Hamerlik, Markus Bredel, Monica E. Burgett, Jann N. Sarkaria, Cathleen R. Carlin, Candece L. Gladson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(22)
Purpose: Bevacizumab, a humanized monoclonal antibody to VEGF, is used routinely in the treatment of patients with recurrent glioblastoma (GBM). However, very little is known regarding the effects of bevacizumab on the cells in the perivascular space
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c144d46cef47372219cbc874717bad31
https://pubmed.ncbi.nlm.nih.gov/28912141
https://pubmed.ncbi.nlm.nih.gov/28912141
Autor:
Gaelle Muller-Greven, Jeongwu Lee, Candece L. Gladson, Bianca-Maria Marin, Edward Reilly, Cathleen R. Carlin, M. Bredel, Jann N. Sarkaria
Publikováno v:
Neuro-Oncology. 20:vi283-vi284
Therapy with ABT-414 (depatux-m), a humanized monoclonal antibody drug conjugate (ADC) directed toward EGFRvIII and activated wild-type EGFR linked to MMAF, has demonstrated promising clinical activity in glioblastoma (GBM) patients with amplified EG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::958996125b7408f40ecf0678bbafa3b6
https://doi.org/10.1093/neuonc/noy148.1182
https://doi.org/10.1093/neuonc/noy148.1182
Autor:
Justin D. Lathia, Petra Hamerlik, Gaelle Muller-Greven, Candece L. Gladson, Manmeet Ahluwalia, Markus Bredel, Steven A. Toms, Cathleen R. Carlin, Jeremy N. Rich
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::390bdc9fd8267e732f653e37e3564eb5
https://europepmc.org/articles/PMC4639244/
https://europepmc.org/articles/PMC4639244/
Autor:
Manmeet Ahluwalia, Petra Hamerlik, Steven A. Toms, Justin D. Lathia, Gaelle Muller-Greven, Markus Bredel, Candece L. Gladson, Jeremy N. Rich, Cathleen R. Carlin
Publikováno v:
Neuro-Oncology. 18:vi188-vi189
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad1745c29fcb32fac251c7749c5aab8d
https://doi.org/10.1093/neuonc/now212.793
https://doi.org/10.1093/neuonc/now212.793
Autor:
Gaelle Muller-Greven, Cathleen R. Carlin, Jeremy N. Rich, Justin D. Lathia, Candece L. Gladson, Petra Hamerlik
Antiangiogenic therapy shows great promise for treatment of cancer. Bevacizumab is a humanized mAb that blocks VEGF-A, thereby inhibiting angiogenesis. It has received FDA approval for patients with recurrent glioblastoma (GBM); however, approximatel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe0492a1b5ba6dd7406dedc489f6a2f1
https://europepmc.org/articles/PMC4218582/
https://europepmc.org/articles/PMC4218582/
Autor:
Gaelle Muller-Greven, Jeremy N. Rich, Wei Michael Liu, Amy S. Nowacki, Monica E. Burgett, Candece L. Gladson, Ping Huang, Clark W. Distelhorst, John C. Kappes, Niladri S. Kar, Justin D. Lathia
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 8, p e70804 (2013)
PLoS ONE, Vol 8, Iss 8, p e70804 (2013)
Members of the Src family kinases (SFK) can modulate diverse cellular processes, including division, death and survival, but their role in autophagy has been minimally explored. Here, we investigated the roles of Lyn, a SFK, in promoting the survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee9e39a0369681a90b83f0c9a6267b0
http://europepmc.org/articles/PMC3732228
http://europepmc.org/articles/PMC3732228
Autor:
Petra Hamerlik, Manmeet Ahluwalia, Jeremy N. Rich, Cathleen R. Carlin, Justin D. Lathia, Markus Bredel, Gaelle Muller-Greven, Steven A. Toms, Candece L. Gladson
Publikováno v:
Cancer Research. 76:3276-3276
Most patients with recurrent glioblastoma (GBM) are treated with bevacizumab, a humanized monoclonal antibody (mAb) that binds VEGF-A and inhibits its binding to VEGFR. Approximately 30% of GBM patients are non-responsive to bevacizumab and the under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c10d4cc7d88bb07b869789e951d84955
https://doi.org/10.1158/1538-7445.am2016-3276
https://doi.org/10.1158/1538-7445.am2016-3276
Autor:
Justin D. Lathia, Petra Hamerlik, Manmeet Ahluwalia, Markus Bredel, Gaelle Muller-Greven, Richard A. Prayson, Jeremy N. Rich, Cathleen R. Carlin, Steven A. Toms, Candece L. Gladson
Publikováno v:
Cancer Research. 75:5226-5226
Antiangiogenic therapy shows great promise for treatment of cancer. Bevacizumab is a humanized mAb that blocks VEGF-A, thereby inhibiting angiogenesis. It has received FDA approval for patients with recurrent glioblastoma (GBM); however, approximatel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0c47c1e44fd7aef14bb546924734ed0
https://doi.org/10.1158/1538-7445.am2015-5226
https://doi.org/10.1158/1538-7445.am2015-5226